Wells Fargo & Company Lyell Immunopharma, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 94,320 shares of LYEL stock, worth $57,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,320
Previous 73,778
27.84%
Holding current value
$57,535
Previous $101,000
40.59%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LYEL
# of Institutions
109Shares Held
163MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$12.3 Million17.35% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.21 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.21 Million14.08% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.23 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA11.9MShares$7.26 Million1.63% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $151M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...